Janesse Marie Gillespie

Recommended Articles

• How Effective is the Morning-After Pill?

  The morning-after pill is a method of emergency contraception to prevent unwanted pregnancy. The components of these pills are levonorgestrel and ulipristal. Emergency contraception is required after unprotected sex to prevent pregnancy. One should take the drug as soon as possible after unprotected...

• Lyrica for Neuropathy

  What is Lyrica?Lyrica, also known as pregabalin, is a drug made for the treatment of seizures in epilepsy. This drug is made to work by restricting nerve impulses that induce seizures. It can also inhibit pain by suppressing pain signal transmissions by the nerves....

• What to Expect After Blepharoplasty

  Blepharoplasty, in simple terms, means the surgery of the eyelid(s). It is performed on either the lower or the upper eyelid. Sometimes, blepharoplasty is also performed on both eyelids (the lower and the upper one). The two major reasons people opt for eyelid surgery are:...

• Lactose Intolerance: Get the Facts

  Lactose intolerance is a digestive problem where the body cannot digest the lactose present in milk and dairy products. Lactose is naturally occurring sugar found in dairy products. It is the main carbohydrate found in all types of milk.In a very small number of cases the production of lactase may...

• Ear Infections: What is Swimmer’s Ear?

  Swimmer’s ear, or otitis external, is the infection of a person's outer ear. It is caused by an inflammation of the external ear canal that extends from the ear pinna to the ear drum. This type of ear infection commonly occurs due to lingering moisture in the ear, followed by a resulting bacterial...

• New Drug for Parkinson's Disease Approved by FDA

  The US Food and Drug Administration (FDA) recently passed a new drug called amantadine extended release capsules to treat dyskinesia in those who have Parkinson’s disease and  are also on medication therapy. The Michael J. Fox Foundation recently created the UNDRS or Unified Dyskinesia Rating...